Beyond Hospital Mergers: The New Front in Healthcare Antitrust
The lawsuit filed February 20, 2026, by the Department of Justice’s Antitrust Division (DOJ) and Ohio Attorney General (Ohio AG) against OhioHealth Corporation isn’t simply about a hospital system getting too big. It’s a signal that regulators are shifting their focus from preventing consolidation to actively dismantling practices that exploit existing market dominance to stifle innovation in healthcare pricing. While hospital mergers have long been scrutinized, this case targets contractual maneuvers – what the DOJ and Ohio AG are calling anti-competitive “gag rules” – that prevent insurers from designing more affordable health plans. The core question isn’t whether OhioHealth is large, but whether it’s using its size to dictate how healthcare is purchased, effectively blocking the development of lower-cost options for consumers.
The allegations center on OhioHealth’s control over inpatient general acute care (GAC) services within the Columbus metropolitan statistical area (ten counties) and a more concentrated “Central Columbus” market (Franklin and Delaware counties). This isn’t a novel market definition – GAC services are routinely used in antitrust cases involving hospitals – but the DOJ and Ohio AG are arguing that OhioHealth has leveraged a market share exceeding 35% (based on both inpatient discharges and bed capacity) to impose restrictive contracts on payors. Attorney General Pam Bondi framed the issue succinctly, stating that “Americans deserve low-cost, high-quality healthcare – not anticompetitive hospital system contracts that make healthcare less affordable.” However, it’s crucial to understand that the lawsuit doesn’t claim OhioHealth is providing low-quality care; rather, it alleges the system can charge higher rates despite receiving lower quality ratings from organizations like Leapfrog and the Centers for Medicare & Medicaid Services (CMS). This highlights a fundamental tension: market share doesn’t automatically equate to value, and a dominant provider can maintain its position even with demonstrably weaker performance metrics.
Based on the original crowell.com report.
The specific conduct under fire involves OhioHealth’s insistence on “take-it-or-leave-it” negotiations, requiring payors to include all of its facilities in their networks, regardless of price, and to position OhioHealth at the most favorable benefit level. This effectively prevents insurers from creating tiered networks, reference-based pricing models, or “budget-conscious” plans that steer patients towards lower-cost providers. The DOJ and Ohio AG claim these restrictions apply to payors covering at least 85% of the commercial health insurance market in Columbus, a remarkably high percentage suggesting a widespread impact. It’s important to note that the government isn’t alleging OhioHealth is directly raising prices; instead, it’s arguing the contracts prevent prices from falling through competitive pressure. Headlines often proclaim the lawsuit aims to “lower healthcare costs,” but the more precise claim is that it seeks to allow market forces to potentially lower costs by removing these contractual barriers.
The Power of “All-or-Nothing” Contracts
The strategy of bundling facilities – demanding inclusion of both urban and rural hospitals – is particularly noteworthy. OhioHealth’s geographic footprint gives it leverage because insurers need access to its entire network to serve their customer base. Payors reportedly attempted to negotiate alternatives, but the DOJ and Ohio AG allege OhioHealth “summarily refused.” This isn’t a case of subtle market manipulation; the government alleges a deliberate and inflexible approach designed to maintain control. This tactic isn’t unique to OhioHealth, and that’s precisely why the outcome of this case will be closely watched. If the DOJ and Ohio AG succeed, it could set a precedent for challenging similar contractual practices employed by large hospital systems across the country. The implications extend beyond Columbus, potentially reshaping how healthcare networks are constructed and negotiated nationwide.
Limitations to Consider
While the allegations are serious, several limitations should be considered. The case hinges on defining the relevant market. OhioHealth’s defense will likely focus on arguing that the Columbus market is broader than the DOJ and Ohio AG contend, encompassing more competing providers and therefore diminishing its market power. Establishing the “Central Columbus” sub-market – consisting of only two counties – is a particularly aggressive move, and its validity will be heavily contested. Furthermore, demonstrating a direct causal link between the contractual restrictions and higher prices will be crucial. While the government alleges a pervasive effect, proving that these contracts specifically prevented lower-cost plan designs from emerging will require substantial evidence. The November 2024 market share update from OhioHealth itself, relied upon by the DOJ and Ohio AG, could be subject to scrutiny regarding its methodology and potential bias.
What Comes Next and Why It Matters
The immediate next steps involve potential motions to dismiss from OhioHealth, challenging the legal basis of the lawsuit. If the case proceeds, discovery will be extensive, involving document requests, depositions, and expert testimony. Private plaintiffs may also emerge, emboldened by the DOJ and Ohio AG’s action. But beyond the legal proceedings, the crucial question is this: if OhioHealth is compelled to alter its contracting practices, will insurers actually design and offer these “budget-conscious” plans? The technical ability to do so will be established, but the willingness to navigate the complexities of tiered networks and reference-based pricing – and to potentially risk alienating a powerful provider – remains uncertain. Healthcare consumers should watch closely to see if this antitrust case translates into tangible changes in their insurance options and out-of-pocket costs in the coming years.
